APOE alleles predict the rate of cognitive decline in Alzheimer disease -: A nonlinear model

被引:179
作者
Martins, CAR
Oulhaj, A
de Jager, CA
Williams, JH
机构
[1] Radcliffe Infirm, OPTIMA, Oxford OX2 6HE, England
[2] Univ Oxford, Dept Pharmacol, Oxford Project Invest Memory & Ageing, Oxford OX1 2JD, England
关键词
D O I
10.1212/01.wnl.0000188871.74093.12
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The APOE genotype predicts the age at onset of Alzheimer disease (AD) and neuropathologic progression. However, studies relating APOE alleles to the rate of cognitive decline have been inconclusive. This may stem from their use of linear statistical analyses. Objective: To model relations of APOE alleles to the rate of cognitive decline in AD, nonlinearly. Methods: Serial measures of cognitive ability were obtained using the cognitive scale of the Cambridge Examination for Mental Disorders of the Elderly in 218 patients with AD. The relations of these serial scores to APOE alleles were tested using nonlinear and linear mixed-effects models. Results: In the non-linear model, possession of an APOE epsilon 4 allele related to earlier and faster cognitive decline, but possession of an APOE epsilon 2 related to slower decline. Patients homozygous for APOE epsilon 4 showed faster cognitive decline than heterozygotes. The linear model was less sensitive and did not detect differences between APOE epsilon 4 homo- and heterozygotes. Conclusions: APOE genotype strongly predicts the rate of cognitive decline in Alzheimer disease. The decline shows a dose-response relation with the APOE epsilon 4 allele, but the APOE epsilon 2 allele is protective. The nonlinear model yielded larger estimates of the maximal rate of decline than the linear.
引用
收藏
页码:1888 / 1893
页数:6
相关论文
共 58 条
[1]   ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease [J].
Asada, T ;
Kariya, T ;
Yamagata, Z ;
Kinoshita, T ;
Asaka, A .
NEUROLOGY, 1996, 47 (02) :603-603
[2]   Placement of dementia sufferers in residential and nursing home care [J].
Bannister, C ;
Ballard, C ;
Lana, M ;
Fairbairn, A ;
Wilcock, G .
AGE AND AGEING, 1998, 27 (02) :189-193
[3]   Apolipoprotein E ε4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias [J].
Barber, R ;
Gholkar, A ;
Scheltens, P ;
Ballard, C ;
McKeith, IG ;
Morris, CM ;
O'Brien, JT .
ARCHIVES OF NEUROLOGY, 1999, 56 (08) :961-965
[4]   Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer's disease [J].
Bennett, DA ;
Wilson, RS ;
Schneider, JA ;
Evans, DA ;
Aggarwal, NT ;
Arnold, SE ;
Cochran, EJ ;
Berry-Kravis, E ;
Bienias, JL .
NEUROLOGY, 2003, 60 (02) :246-252
[5]   PROTECTIVE EFFECT OF APOLIPOPROTEIN-E TYPE-2 ALLELE FOR LATE-ONSET ALZHEIMER-DISEASE [J].
CORDER, EH ;
SAUNDERS, AM ;
RISCH, NJ ;
STRITTMATTER, WJ ;
SCHMECHEL, DE ;
GASKELL, PC ;
RIMMLER, JB ;
LOCKE, PA ;
CONNEALLY, PM ;
SCHMADER, KE ;
SMALL, GW ;
ROSES, AD ;
HAINES, JL ;
PERICAKVANCE, MA .
NATURE GENETICS, 1994, 7 (02) :180-184
[6]   GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].
CORDER, EH ;
SAUNDERS, AM ;
STRITTMATTER, WJ ;
SCHMECHEL, DE ;
GASKELL, PC ;
SMALL, GW ;
ROSES, AD ;
HAINES, JL ;
PERICAKVANCE, MA .
SCIENCE, 1993, 261 (5123) :921-923
[7]   Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer's disease [J].
Craft, S ;
Teri, L ;
Edland, SD ;
Kukull, WA ;
Schellenberg, G ;
McCormick, WC ;
Bowen, JD ;
Larson, EB .
NEUROLOGY, 1998, 51 (01) :149-153
[8]  
DalForno G, 1996, ARCH NEUROL-CHICAGO, V53, P345
[9]   Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease [J].
de Jager, CA ;
Hogervorst, E ;
Combrinck, M ;
Budge, MM .
PSYCHOLOGICAL MEDICINE, 2003, 33 (06) :1039-1050
[10]   The CAMCOG: A useful screening instrument for dementia in stroke patients [J].
de Koning, I ;
van Kooten, F ;
Dippel, DWJ ;
van Harskamp, F ;
Grobbee, DE ;
Kluft, C ;
Koudstaal, PJ .
STROKE, 1998, 29 (10) :2080-2086